ID

15159

Description

Octreotide LAR as Maintenance Treatment for Patients With NEC; ODM derived from: https://clinicaltrials.gov/show/NCT02409849

Lien

https://clinicaltrials.gov/show/NCT02409849

Mots-clés

Versions (2)
  1. 20/05/2016 20/05/2016 -
  2. 20/05/2016 20/05/2016 - Julian Varghese
Téléchargé le

20 mai 2016

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY-NC 3.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Gastro-entero-pancreatic Carcinoma NCT02409849

Anglais

Eligibility Gastro-entero-pancreatic Carcinoma NCT02409849

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. histologic diagnosis of high grade (poorly differentiated) gastro-entero-pancreatic neuroendocrine carcinoma.
Description

Neuroendocrine Tumors Severe Poorly differentiated | Enteroendocrine Cell

Type de données

boolean

Alias
UMLS CUI [1,1]
C0206754
UMLS CUI [1,2]
C0205082
UMLS CUI [1,3]
C0205617
UMLS CUI [2]
C0524979
2. high grade neuroendocrine carcinoma of esophageal or unknown primary site (if a pulmonary primary has been excluded)
Description

Neuroendocrine Carcinoma Severe | Site Esophageal

Type de données

boolean

Alias
UMLS CUI [1,1]
C0206695
UMLS CUI [1,2]
C0205082
UMLS CUI [2,1]
C1515974
UMLS CUI [2,2]
C1522619
3. metastatic or unresectable disease
Description

Metastatic Neoplasm | Unresectable Malignant Neoplasm

Type de données

boolean

Alias
UMLS CUI [1]
C2939420
UMLS CUI [2]
C1336869
4. measurable disease
Description

Measurable Disease

Type de données

boolean

Alias
UMLS CUI [1]
C1513041
5. accepted chemotherapy with ep or ip regimen for no less than three months
Description

Chemotherapy Regimen | cisplatin/etoposide protocol | cisplatin/irinotecan

Type de données

boolean

Alias
UMLS CUI [1]
C0392920
UMLS CUI [2]
C0078414
UMLS CUI [3]
C0281724
6. effectiveness with cr/pr/sd
Description

In complete remission | partial response | Stable Disease | Effectiveness

Type de données

boolean

Alias
UMLS CUI [1]
C0677874
UMLS CUI [2]
C1521726
UMLS CUI [3]
C0677946
UMLS CUI [4]
C1280519
7. informed consent
Description

Informed Consent

Type de données

boolean

Alias
UMLS CUI [1]
C0021430
8. performance status of 0 or 1
Description

performance status

Type de données

boolean

Alias
UMLS CUI [1]
C1518965
9. adequate bone marrow function (defined as absolute neutrophil count [anc] >= 1500, platelet count [plt] >= 75,000 and a hemoglobin [hgb] >= 9).
Description

Bone Marrow Function Adequate | Absolute neutrophil count | Platelet Count measurement | Hemoglobin

Type de données

boolean

Alias
UMLS CUI [1,1]
C0005953
UMLS CUI [1,2]
C0031843
UMLS CUI [1,3]
C0205411
UMLS CUI [2]
C0948762
UMLS CUI [3]
C0032181
UMLS CUI [4]
C0019046
10. adequate hepatic function with a bilirubin of <= 2.0 mg/dl, and aspartate aminotransferase (ast or sgot) and alanine aminotransferase (alt or sgpt) <= 2.5 times the upper limits of normal, unless caused by liver metastasis. if caused by metastasis, then should be sgpt and sgot <= 5 times the upper limits of normal.
Description

Liver function Adequate | Bilirubin, total measurement | Aspartate aminotransferase measurement | Alanine aminotransferase measurement

Type de données

boolean

Alias
UMLS CUI [1,1]
C0232741
UMLS CUI [1,2]
C0205411
UMLS CUI [2]
C0201913
UMLS CUI [3]
C0201899
UMLS CUI [4]
C0201836
adequate renal function defined as serum creatinine <= 1.5 mg/dl.
Description

Normal renal function | Creatinine measurement, serum

Type de données

boolean

Alias
UMLS CUI [1]
C0232805
UMLS CUI [2]
C0201976
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. patients who are on ep or ip chemotherapy for less than three months .
Description

Chemotherapy Regimen | cisplatin/etoposide protocol | cisplatin/irinotecan

Type de données

boolean

Alias
UMLS CUI [1]
C0392920
UMLS CUI [2]
C0078414
UMLS CUI [3]
C0281724
2. effectiveness with pd.
Description

Effectiveness Progressive Disease

Type de données

boolean

Alias
UMLS CUI [1,1]
C1280519
UMLS CUI [1,2]
C1335499
3. patients with brain metastases are not eligible.
Description

Metastatic malignant neoplasm to brain

Type de données

boolean

Alias
UMLS CUI [1]
C0220650
4. patients with new york heart association (nyha) class iii or iv heart disease are not eligible as well as those patients with history of angina, myocardial infarction, or congestive heart failure within six months.
Description

Heart failure NYHA class III | Heart failure NYHA class IV | Angina Pectoris | Myocardial Infarction | Congestive heart failure

Type de données

boolean

Alias
UMLS CUI [1]
C1536132
UMLS CUI [2]
C1536133
UMLS CUI [3]
C0002962
UMLS CUI [4]
C0027051
UMLS CUI [5]
C0018802
5. pregnant or lactating women. all women of child bearing potential must have a negative pregnancy test prior to entry into the study. all patients of child bearing potential must be advised of the importance of avoiding pregnancy and using appropriate methods of contraception while participating in this investigational trial.
Description

Pregnancy | Breast Feeding | Childbearing Potential Pregnancy test negative Contraceptive methods

Type de données

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3,1]
C3831118
UMLS CUI [3,2]
C0427780
UMLS CUI [3,3]
C0700589
6. patients with serious complicated infections, or nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the complications of this therapy.
Description

Complicated infection Serious | Illness Non-Malignant Uncontrolled | Therapeutic procedure risk control

Type de données

boolean

Alias
UMLS CUI [1,1]
C3160894
UMLS CUI [1,2]
C0205404
UMLS CUI [2,1]
C0221423
UMLS CUI [2,2]
C1518371
UMLS CUI [2,3]
C0205318
UMLS CUI [3,1]
C0087111
UMLS CUI [3,2]
C1444641
UMLS CUI [3,3]
C0243148
7. patients with psychiatric disorders rendering them incapable of complying with the requirements of the protocol.
Description

Mental disorders Compliance behavior Limited

Type de données

boolean

Alias
UMLS CUI [1,1]
C0004936
UMLS CUI [1,2]
C1321605
UMLS CUI [1,3]
C0439801
8. patients with serum calcium > 12 mg/dl or symptomatic hypercalcemia under treatment.
Description

Serum calcium measurement | Therapeutic procedure Hypercalcemia Symptomatic

Type de données

boolean

Alias
UMLS CUI [1]
C0728876
UMLS CUI [2,1]
C0087111
UMLS CUI [2,2]
C0020437
UMLS CUI [2,3]
C0231220
9. patients with osseous metastasis as only site of disease.
Description

Secondary malignant neoplasm of bone | Site Single Disease

Type de données

boolean

Alias
UMLS CUI [1]
C0153690
UMLS CUI [2,1]
C1515974
UMLS CUI [2,2]
C0205171
UMLS CUI [2,3]
C0012634
10. patients with any concurrent active malignancy other than non-melanoma skin cancers or carcinoma-in-situ of the cervix. patients with previous malignancies but without evidence of disease for > 5 years will be allowed to enter the trial.
Description

Malignant Neoplasms Concurrent | Skin carcinoma | Carcinoma in situ of uterine cervix

Type de données

boolean

Alias
UMLS CUI [1,1]
C0006826
UMLS CUI [1,2]
C0205420
UMLS CUI [2]
C0699893
UMLS CUI [3]
C0851140
11. patients with known gilbert's syndrome are ineligible.
Description

Gilbert Disease

Type de données

boolean

Alias
UMLS CUI [1]
C0017551
Retour au début de la page

Similar models

Eligibility Gastro-entero-pancreatic Carcinoma NCT02409849

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Neuroendocrine Tumors Severe Poorly differentiated | Enteroendocrine Cell
Item
1. histologic diagnosis of high grade (poorly differentiated) gastro-entero-pancreatic neuroendocrine carcinoma.
boolean
C0206754 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0205617 (UMLS CUI [1,3])
C0524979 (UMLS CUI [2])
Neuroendocrine Carcinoma Severe | Site Esophageal
Item
2. high grade neuroendocrine carcinoma of esophageal or unknown primary site (if a pulmonary primary has been excluded)
boolean
C0206695 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C1515974 (UMLS CUI [2,1])
C1522619 (UMLS CUI [2,2])
Metastatic Neoplasm | Unresectable Malignant Neoplasm
Item
3. metastatic or unresectable disease
boolean
C2939420 (UMLS CUI [1])
C1336869 (UMLS CUI [2])
Measurable Disease
Item
4. measurable disease
boolean
C1513041 (UMLS CUI [1])
Chemotherapy Regimen | cisplatin/etoposide protocol | cisplatin/irinotecan
Item
5. accepted chemotherapy with ep or ip regimen for no less than three months
boolean
C0392920 (UMLS CUI [1])
C0078414 (UMLS CUI [2])
C0281724 (UMLS CUI [3])
In complete remission | partial response | Stable Disease | Effectiveness
Item
6. effectiveness with cr/pr/sd
boolean
C0677874 (UMLS CUI [1])
C1521726 (UMLS CUI [2])
C0677946 (UMLS CUI [3])
C1280519 (UMLS CUI [4])
Informed Consent
Item
7. informed consent
boolean
C0021430 (UMLS CUI [1])
performance status
Item
8. performance status of 0 or 1
boolean
C1518965 (UMLS CUI [1])
Bone Marrow Function Adequate | Absolute neutrophil count | Platelet Count measurement | Hemoglobin
Item
9. adequate bone marrow function (defined as absolute neutrophil count [anc] >= 1500, platelet count [plt] >= 75,000 and a hemoglobin [hgb] >= 9).
boolean
C0005953 (UMLS CUI [1,1])
C0031843 (UMLS CUI [1,2])
C0205411 (UMLS CUI [1,3])
C0948762 (UMLS CUI [2])
C0032181 (UMLS CUI [3])
C0019046 (UMLS CUI [4])
Liver function Adequate | Bilirubin, total measurement | Aspartate aminotransferase measurement | Alanine aminotransferase measurement
Item
10. adequate hepatic function with a bilirubin of <= 2.0 mg/dl, and aspartate aminotransferase (ast or sgot) and alanine aminotransferase (alt or sgpt) <= 2.5 times the upper limits of normal, unless caused by liver metastasis. if caused by metastasis, then should be sgpt and sgot <= 5 times the upper limits of normal.
boolean
C0232741 (UMLS CUI [1,1])
C0205411 (UMLS CUI [1,2])
C0201913 (UMLS CUI [2])
C0201899 (UMLS CUI [3])
C0201836 (UMLS CUI [4])
Normal renal function | Creatinine measurement, serum
Item
adequate renal function defined as serum creatinine <= 1.5 mg/dl.
boolean
C0232805 (UMLS CUI [1])
C0201976 (UMLS CUI [2])
Item Group
C0680251 (UMLS CUI)
Chemotherapy Regimen | cisplatin/etoposide protocol | cisplatin/irinotecan
Item
1. patients who are on ep or ip chemotherapy for less than three months .
boolean
C0392920 (UMLS CUI [1])
C0078414 (UMLS CUI [2])
C0281724 (UMLS CUI [3])
Effectiveness Progressive Disease
Item
2. effectiveness with pd.
boolean
C1280519 (UMLS CUI [1,1])
C1335499 (UMLS CUI [1,2])
Metastatic malignant neoplasm to brain
Item
3. patients with brain metastases are not eligible.
boolean
C0220650 (UMLS CUI [1])
Heart failure NYHA class III | Heart failure NYHA class IV | Angina Pectoris | Myocardial Infarction | Congestive heart failure
Item
4. patients with new york heart association (nyha) class iii or iv heart disease are not eligible as well as those patients with history of angina, myocardial infarction, or congestive heart failure within six months.
boolean
C1536132 (UMLS CUI [1])
C1536133 (UMLS CUI [2])
C0002962 (UMLS CUI [3])
C0027051 (UMLS CUI [4])
C0018802 (UMLS CUI [5])
Pregnancy | Breast Feeding | Childbearing Potential Pregnancy test negative Contraceptive methods
Item
5. pregnant or lactating women. all women of child bearing potential must have a negative pregnancy test prior to entry into the study. all patients of child bearing potential must be advised of the importance of avoiding pregnancy and using appropriate methods of contraception while participating in this investigational trial.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C3831118 (UMLS CUI [3,1])
C0427780 (UMLS CUI [3,2])
C0700589 (UMLS CUI [3,3])
Complicated infection Serious | Illness Non-Malignant Uncontrolled | Therapeutic procedure risk control
Item
6. patients with serious complicated infections, or nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the complications of this therapy.
boolean
C3160894 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0221423 (UMLS CUI [2,1])
C1518371 (UMLS CUI [2,2])
C0205318 (UMLS CUI [2,3])
C0087111 (UMLS CUI [3,1])
C1444641 (UMLS CUI [3,2])
C0243148 (UMLS CUI [3,3])
Mental disorders Compliance behavior Limited
Item
7. patients with psychiatric disorders rendering them incapable of complying with the requirements of the protocol.
boolean
C0004936 (UMLS CUI [1,1])
C1321605 (UMLS CUI [1,2])
C0439801 (UMLS CUI [1,3])
Serum calcium measurement | Therapeutic procedure Hypercalcemia Symptomatic
Item
8. patients with serum calcium > 12 mg/dl or symptomatic hypercalcemia under treatment.
boolean
C0728876 (UMLS CUI [1])
C0087111 (UMLS CUI [2,1])
C0020437 (UMLS CUI [2,2])
C0231220 (UMLS CUI [2,3])
Secondary malignant neoplasm of bone | Site Single Disease
Item
9. patients with osseous metastasis as only site of disease.
boolean
C0153690 (UMLS CUI [1])
C1515974 (UMLS CUI [2,1])
C0205171 (UMLS CUI [2,2])
C0012634 (UMLS CUI [2,3])
Malignant Neoplasms Concurrent | Skin carcinoma | Carcinoma in situ of uterine cervix
Item
10. patients with any concurrent active malignancy other than non-melanoma skin cancers or carcinoma-in-situ of the cervix. patients with previous malignancies but without evidence of disease for > 5 years will be allowed to enter the trial.
boolean
C0006826 (UMLS CUI [1,1])
C0205420 (UMLS CUI [1,2])
C0699893 (UMLS CUI [2])
C0851140 (UMLS CUI [3])
Gilbert Disease
Item
11. patients with known gilbert's syndrome are ineligible.
boolean
C0017551 (UMLS CUI [1])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial